Bonesupport Holding AB (publ) (STO:BONEX)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 14.32B |
| Revenue (ttm) | 1.22B |
| Net Income (ttm) | 185.11M |
| Shares Out | 65.86M |
| EPS (ttm) | 2.77 |
| PE Ratio | 78.47 |
| Forward PE | 40.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 350,411 |
| Average Volume | 351,834 |
| Open | 225.80 |
| Previous Close | 226.40 |
| Day's Range | 216.60 - 225.80 |
| 52-Week Range | 165.00 - 346.40 |
| Beta | 0.45 |
| RSI | 44.23 |
| Earnings Date | Apr 22, 2026 |
About Bonesupport Holding AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute t... [Read more]
Financial Performance
In 2025, Bonesupport Holding AB's revenue was 1.17 billion, an increase of 30.70% compared to the previous year's 898.73 million. Earnings were 142.15 million, an increase of 6.28%.
Financial StatementsNews
Bonesupport Holding AB Earnings Call Transcript: Q1 2026
Net sales grew 31% at constant exchange rates, driven by strong U.S. CERAMENT G performance and solid European growth. Adjusted operating margin improved to 26%, with robust cash flow and positive CMS reimbursement developments supporting future outlook.
Bonesupport Holding AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 22% reported sales growth (36% at constant FX), driven by strong U.S. CERAMENT G adoption and expansion into trauma centers. Guidance for 2026 targets at least 35% constant FX growth, with upside from potential CERAMENT V approval.
Bonesupport Holding AB Earnings Call Transcript: Q3 2025
Q3 2025 saw 24% sales growth (34% at constant currency), a 27% adjusted operating margin, and strong cash flow. U.S. CERAMENT G sales drove performance, with new clinical evidence supporting expansion into revision arthroplasty. Full-year guidance for 40%+ sales growth is reiterated.
Bonesupport Holding AB Earnings Call Transcript: Q2 2025
Q2 2025 saw 29% reported sales growth (40% in constant currency), driven by CERAMENT G's strong U.S. performance and stable margins. Guidance for over 40% sales growth in constant currency is reaffirmed, with new product launches and favorable reimbursement changes expected to support future growth.
Bonesupport Holding AB Earnings Call Transcript: Q1 2025
Q1 2025 saw 54% sales growth, driven by U.S. CERAMENT G adoption and strong cash flow. CMS proposed significant NTAP reimbursement, CERAMENT V was submitted to the FDA, and market share gains continued in Europe. Guidance for 2025 is sales growth above 40%.
Bonesupport Holding AB Earnings Call Transcript: Q4 2024
Q4 2024 saw 49% sales growth and record cash flow, led by CERAMENT G's US success and strong clinical evidence. Guidance for 2025 targets over 40% sales growth, with ongoing expansion into new markets and continued high gross margins.
Bonesupport Holding AB Earnings Call Transcript: Q3 2024
Q3 2024 saw over 50% sales growth year-over-year, driven by CERAMENT G's rapid U.S. adoption and strong global performance. The SOLARIO study supports reduced systemic antibiotic use, and new market segments like open trauma and spinal fusion are expected to fuel future growth.
Bonesupport Holding AB Earnings Call Transcript: Q2 2024
Q2 2024 saw 57% year-over-year sales growth to SEK 220 million, led by U.S. CERAMENT G uptake and strong market share gains. Gross margin remained high at 95.8%, and 2024 sales guidance was raised to over 50% growth in constant currency.